Sinovac Biotech COVID vaccine CoronaVac conditionally registered in South Africa
China: Sinovac Biotech Ltd. has announced that the South African Health Products Regulatory Authority (SAHPRA) has granted conditional registration to SINOVAC CoronaVac in aged 18 and above adults, based on acceptable safety, quality, and efficacy data submitted. The vaccine is administered intramuscularly in two doses with a 14 to 28-day interval.
The CoronaVac was previously authorized for emergency use with conditions by the SAHPRA on July 3, 2021.
SINOVAC COVID-19 vaccine has been available in more than 60 countries, with a total supply of almost 2.9 billion doses.
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.
Read also: Sinovac CoronaVac shot gets strong boost from Pfizer, AstraZeneca, JnJ COVID doses, claims study
SINOVAC's COVID-19 vaccine, CoronaVac, has been approved for use in more than 60 countries and regions worldwide. The Healive, a hepatitis A vaccine manufactured by the Company, passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, Inlive, is an innovative vaccine, that was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) was prequalified by WHO.
The Company is also the supplier of the H5N1 pandemic influenza vaccine, Panflu, to the Chinese government stockpiling program.
Read also: WHO prequalifies Sinovac Polio vaccine
